Andrea Gallina
Andrea Gallina has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Elisabetta Gabano
Dipartimento per lo Sviluppo Sostenibile e la Transizione Ecologica, Università del Piemonte Orientale, Piazza S. Eusebio 5, 13100 Vercelli, Italy
3 shared publications - Mauro Ravera
Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale “A. Avogadro”, Alessandria, Italy
3 shared publications - Beatrice Rangone
Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, 15121 Alessandria, Italy
2 shared publications - Domenico Osella
Dipartimento di Scienze e Innovazione Tecnologica Università del Piemonte Orientale Viale T. Michel 11 15121 Alessandria Italy
2 shared publications - Ilaria Zanellato
Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, 15121 Alessandria, Italy
2 shared publications Stefano Tinello
Dipartimento di Scienze e Innovazione Tecnologica, Università del Piemonte Orientale, 15121 Alessandria, Italy
2 shared publications
Latest Publications
- Open Access
- 1 October 2021
- Published by Elsevier in Human Immunology
- Vol. 82 (10) , 758-766
Availability of HLA-allele-matched unrelated donors and registry size: Estimation from haplotype frequency in the Italian population
- 1 October 2021
- Published by Elsevier in Human Immunology
- Vol. 82 (10) , 758-766
Open AccessAvailability of HLA-allele-matched unrelated donors and registry size: Estimation from haplotype frequency in the Italian population
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S624
Molecular characterization of residual bladder cancer after pembrolizumab
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S624
Molecular characterization of residual bladder cancer after pembrolizumab
- 22 July 2020
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (34) , 7696-7712
Supramolecular hydrogels based on custom-made poly(ether urethane)s and cyclodextrins as potential drug delivery vehicles: design and characterization
A library of poly(ether urethane)-based supramolecular hydrogels was designed, showing quick gelation, no phase separation, remarkable mechanical and self-healing properties.
- 22 July 2020
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 8 (34) , 7696-7712
Supramolecular hydrogels based on custom-made poly(ether urethane)s and cyclodextrins as potential drug delivery vehicles: design and characterization
A library of poly(ether urethane)-based supramolecular hydrogels was designed, showing quick gelation, no phase separation, remarkable mechanical and self-healing properties.
- 31 May 2018
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 47 (25) , 8268-8282
The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions
Multi-action cisplatin-based mono- (1) and di-clofibric acid (2) Pt(IV) “combo” derivatives were synthesized via both traditional and microwave assisted procedures. The two complexes offered very good performances (IC50 values in a nanomolar range) on a panel of human tumor cell lines, including the highly chemoresistant malignant pleural mesothelioma ones. Moreover, both 1 and 2 bypass the cisplatin resistance. Indeed, cisplatin and clofibric acid, the metabolites of the Pt(IV) → Pt(II) intracellular reduction, proved to act synergistically. The adjuvant action of clofibric acid relies on the activation of peroxisome proliferator-activated receptor α (PPARα) that, in turn, decreases the level of Hypoxia-Inducible Factor-1α. Both compounds induced extensive apoptosis in tumor cells, also via oxidative stress. Finally, 2 exhibited excellent performances also under the hypoxic conditions typical of solid tumors, where cisplatin is less effective.
- 31 May 2018
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 47 (25) , 8268-8282
The cisplatin-based Pt(iv)-diclorofibrato multi-action anticancer prodrug exhibits excellent performances also under hypoxic conditions
Multi-action cisplatin-based mono- (1) and di-clofibric acid (2) Pt(IV) “combo” derivatives were synthesized via both traditional and microwave assisted procedures. The two complexes offered very good performances (IC50 values in a nanomolar range) on a panel of human tumor cell lines, including the highly chemoresistant malignant pleural mesothelioma ones. Moreover, both 1 and 2 bypass the cisplatin resistance. Indeed, cisplatin and clofibric acid, the metabolites of the Pt(IV) → Pt(II) intracellular reduction, proved to act synergistically. The adjuvant action of clofibric acid relies on the activation of peroxisome proliferator-activated receptor α (PPARα) that, in turn, decreases the level of Hypoxia-Inducible Factor-1α. Both compounds induced extensive apoptosis in tumor cells, also via oxidative stress. Finally, 2 exhibited excellent performances also under the hypoxic conditions typical of solid tumors, where cisplatin is less effective.
- 22 September 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (41) , 14174-14185
An unsymmetric cisplatin-based Pt( iv ) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate
The design, synthesis, characterization and biological properties of a Pt(IV) complex containing the very active inhibitor of histone deacetylase (2-propynyl)octanoic acid, POA, as an axial ligand are reported here. The title complex, namely (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(IV), 1, containing POA in racemic or in enantiomeric forms, was one/two orders of magnitude more active than cisplatin, depending on the chemo-sensitivity of the cancer cell lines. Moreover, 1 exhibited similar or even better antiproliferative activity than (OC-6-33)-diamminedichloridobis(2-propylpentanoato)platinum(IV), 2, containing two molecules of the well-known histone deacetylase inhibitor 2-propylpentanoic (valproic) acid. The high potency of 1 is likely due to its high cellular accumulation and to the synergism between the DNA-damaging cisplatin and the histone deacetylase inhibitor POA, both released upon the intracellular reduction of 1. Prodrug 1, after oral administration, caused an impressive reduction of the tumor mass (94%) in a model of solid tumor (murine Lewis lung carcinoma), compared to that of the control, whereas (intraperitoneal) cisplatin induced a tumor regression of 75% only. A good accumulation of 1 was observed in the tumor mass. The time course of the body weight attested that cisplatin induced elevated anorexia, whereas treatment with 1 did not induce significant body weight loss throughout the therapeutic experiment.
- 22 September 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (41) , 14174-14185
An unsymmetric cisplatin-based Pt( iv ) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate
The design, synthesis, characterization and biological properties of a Pt(IV) complex containing the very active inhibitor of histone deacetylase (2-propynyl)octanoic acid, POA, as an axial ligand are reported here. The title complex, namely (OC-6-44)-acetatodiamminedichlorido(2-(2-propynyl)octanoato)platinum(IV), 1, containing POA in racemic or in enantiomeric forms, was one/two orders of magnitude more active than cisplatin, depending on the chemo-sensitivity of the cancer cell lines. Moreover, 1 exhibited similar or even better antiproliferative activity than (OC-6-33)-diamminedichloridobis(2-propylpentanoato)platinum(IV), 2, containing two molecules of the well-known histone deacetylase inhibitor 2-propylpentanoic (valproic) acid. The high potency of 1 is likely due to its high cellular accumulation and to the synergism between the DNA-damaging cisplatin and the histone deacetylase inhibitor POA, both released upon the intracellular reduction of 1. Prodrug 1, after oral administration, caused an impressive reduction of the tumor mass (94%) in a model of solid tumor (murine Lewis lung carcinoma), compared to that of the control, whereas (intraperitoneal) cisplatin induced a tumor regression of 75% only. A good accumulation of 1 was observed in the tumor mass. The time course of the body weight attested that cisplatin induced elevated anorexia, whereas treatment with 1 did not induce significant body weight loss throughout the therapeutic experiment.
- 12 July 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (31) , 10246-10254
How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)]+
Oxidation of [Pt(II)Cl(terpy)]+ (terpy = 2,2′:6′,2′′-terpyridine) has been attempted with several oxidizing agents and under different experimental conditions in order to obtain a Pt(IV) complex suitable for the conjugation to nanovectors to be used in drug delivery targeting for anticancer therapy. The best compromise in terms of yield and purity of the final complex was obtained by microwave-assisted reaction at 70 °C in 50% aqueous H2O2 for 2 h. Under these conditions the quantitative formation of [Pt(IV)Cl(OH)2(terpy)]+ was observed. The subsequent synthetic steps were, (i) functionalization of [Pt(IV)Cl(OH)2(terpy)]+ in the axial position with succinic anhydride to obtain [Pt(IV)Cl(OH)(succinato)(terpy)]+ and (ii) reaction of the latter with nonporous silica nanoparticles (SNPs) with an external shell containing primary amino groups to obtain a nanovector able to transport the Pt(IV) antitumor prodrug in the form of a conjugate Pt-SNP. Finally, the antiproliferative activity and cell accumulation of [Pt(II)Cl(terpy)]+, [Pt(IV)Cl(OH)2(terpy)]+, and the Pt-SNP conjugate were measured on three cancer cell lines. Despite highly effective accumulation of Pt-SNP in cells, a modest increase in activity was observed with respect to the molecular species. Further experiments showed that the Pt-SNP conjugate can release [Pt(II)Cl(terpy)]+ upon reduction, but this metabolite may undergo hydrolysis, and the resulting aquo complex could coordinate once again the free amino groups of the SNPs. In the resulting tetraamine form, the Pt(II) complex conjugated to the SNPs cannot completely perform its antiproliferative activity.
- 12 July 2017
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 46 (31) , 10246-10254
How to obtain Pt(iv) complexes suitable for conjugation to nanovectors from the oxidation of [PtCl(terpyridine)]+
Oxidation of [Pt(II)Cl(terpy)]+ (terpy = 2,2′:6′,2′′-terpyridine) has been attempted with several oxidizing agents and under different experimental conditions in order to obtain a Pt(IV) complex suitable for the conjugation to nanovectors to be used in drug delivery targeting for anticancer therapy. The best compromise in terms of yield and purity of the final complex was obtained by microwave-assisted reaction at 70 °C in 50% aqueous H2O2 for 2 h. Under these conditions the quantitative formation of [Pt(IV)Cl(OH)2(terpy)]+ was observed. The subsequent synthetic steps were, (i) functionalization of [Pt(IV)Cl(OH)2(terpy)]+ in the axial position with succinic anhydride to obtain [Pt(IV)Cl(OH)(succinato)(terpy)]+ and (ii) reaction of the latter with nonporous silica nanoparticles (SNPs) with an external shell containing primary amino groups to obtain a nanovector able to transport the Pt(IV) antitumor prodrug in the form of a conjugate Pt-SNP. Finally, the antiproliferative activity and cell accumulation of [Pt(II)Cl(terpy)]+, [Pt(IV)Cl(OH)2(terpy)]+, and the Pt-SNP conjugate were measured on three cancer cell lines. Despite highly effective accumulation of Pt-SNP in cells, a modest increase in activity was observed with respect to the molecular species. Further experiments showed that the Pt-SNP conjugate can release [Pt(II)Cl(terpy)]+ upon reduction, but this metabolite may undergo hydrolysis, and the resulting aquo complex could coordinate once again the free amino groups of the SNPs. In the resulting tetraamine form, the Pt(II) complex conjugated to the SNPs cannot completely perform its antiproliferative activity.